Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Point-of-care testing and home testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound

Research output: Contribution to journalReviewResearchpeer-review

  1. Loss of sucrase-isomaltase function increases acetate levels and improves metabolic health in Greenlandic cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Validation and Update of the Lemann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Challenges and Opportunities in IBD Clinical Trial Design

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply

    Research output: Contribution to journalLetterResearchpeer-review

  2. ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for non-invasive inflammatory bowel disease monitoring in the tight control model.

Original languageEnglish
JournalGastroenterology
Volume162
Issue number5
Pages (from-to)1476-1492
Number of pages17
ISSN0016-5085
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Colitis, Ulcerative/metabolism, Crohn Disease/metabolism, Humans, Inflammatory Bowel Diseases/diagnostic imaging, Point-of-Care Testing, Ultrasonography, Biomarker, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, eHealth

ID: 70586299